Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
NCT00553722 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2007-11-06
Summary
It is well known that Aldosterone (aldo) can cause hypertension (HBP). Since aldo is known to cause the kidney to retain sodium (Na) and Na retention is known to cause HBP, it has been thought that the mechanism by which aldo causes HBP is by Na retention. Recent studies have suggested that aldo has many effects in addition to its ability to cause the kidney to retain Na. To test the hypothesis that aldo can cause HBP in a manner which does not involve Na retention, we plan, in this protocol, to give Eplerenone, a specific aldo antagonist, to patients on dialysis who have HBP. A positive effect of Eplerenone to lower HBP in these patients would support this hypothesis.
Conditions
- Hypertension
- Dialysis
- Hyperaldosteronism
Interventions
- DRUG
-
Eplerenone
Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
- DRUG
-
Administer a placebo tablet orally twice daily for 4 weeks.
Sponsors & Collaborators
-
Shaare Zedek Medical Center
lead OTHER
Principal Investigators
-
Linda Shavit, MD · Shaare Zedek Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- TRIPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 16 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
- Completion
- 2009-11-30
Countries
- Israel
Study Locations
More Related Trials
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
NCT05925569 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
NCT03020303 ·Status: COMPLETED ·Phase: PHASE3
-
Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
NCT03683069 ·Status: COMPLETED ·Phase: PHASE4
-
Aldosterone Blockade in Heart Failure
NCT00523757 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Aldosterone Blockade on Arterial Compliance
NCT01089309 ·Status: COMPLETED ·Phase: PHASE4
-
Steroids on Intra-dialytic Hypotension
NCT03465007 ·Status: COMPLETED ·Phase: NA
-
The Plasma Metabolomics Profiling of Primary Aldosteronism
NCT06500000 ·Status: COMPLETED
-
Multi-omics Studies of Primary Aldosteronism
NCT07111351 ·Status: RECRUITING
-
Prospective Phenotyping of Autonomous Aldosterone Secretion
NCT03484130 ·Status: ACTIVE_NOT_RECRUITING
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
NCT05030545 ·Status: RECRUITING ·Phase: PHASE4
-
Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart
NCT01944384 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension
NCT00138944 ·Status: COMPLETED ·Phase: PHASE3
-
Eplerenone in Hemodialysis Trial
NCT01650012 ·Status: COMPLETED ·Phase: NA
-
RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough
NCT01805362 ·Status: COMPLETED ·Phase: NA
-
Alkalinization by Urologists & Nephrologists
NCT03035812 ·Status: COMPLETED ·Phase: PHASE4
-
Outcome of Patients With Primary Aldosteronism
NCT04428827 ·Status: UNKNOWN
-
Efficacy of Diuretics in Kidney Disease
NCT04542304 ·Status: TERMINATED ·Phase: PHASE2
-
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
NCT00980031 ·Status: TERMINATED ·Phase: NA
-
The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production
NCT02871648 ·Status: COMPLETED ·Phase: PHASE1
-
Diagnosing Variable Primary Aldosteronism.
NCT05765786 ·Status: RECRUITING
-
Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism
NCT03174847 ·Status: COMPLETED
-
The Diagnostic Performance of 24-hour Urinary Aldosterone for Primary Aldosteronism
NCT06236698 ·Status: COMPLETED
-
Aldosterone Antagonism in Diastolic Heart Failure
NCT00108251 ·Status: COMPLETED ·Phase: PHASE4
-
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
NCT00732771 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Statin Use on Aldosterone Secretion
NCT02871687 ·Status: COMPLETED ·Phase: PHASE1